{
  "links": "https://www.ycombinator.com/companies/gen1e-lifesciences",
  "name": "GEn1E Lifesciences",
  "headline": "AI platform accelerating therapies for rare & inflammatory diseases.",
  "batch": "S19",
  "description": "GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities‚Äîcreating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). \r\n\nGEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital‚Äîa stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry.\r\n\nWith ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need.\r\n\nThe team at GEn1E has decades of experience in drug development and machine learning. We graduated from YCombinator and Stanford-StartX in late 2019. We are based in Palo Alto, CA.",
  "activity_status": "Active",
  "website": "https://www.gen1e.com",
  "founded_date": 2018.0,
  "team_size": null,
  "location": "Palo Alto",
  "group_partner": "Jared Friedman",
  "group_partner_yc": "https://www.ycombinator.com/people/jared-friedman",
  "company_linkedin": null,
  "company_twitter": null,
  "tags": "industry:artificial-intelligence; industry:biotech; industry:healthcare; industry:drug-discovery; location:san-francisco-bay-area",
  "founders": [],
  "status": true,
  "markdown": "raw_markdown='[![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/66395347210378818f4c651d_GEn1E%20logo%20horizontal%20\\\\(2\\\\).svg)](https://www.gen1e.com/</>)\\n[Pipeline](https://www.gen1e.com/</pipeline>)[Differentiation](https://www.gen1e.com/</differentiation>)[AI Platform](https://www.gen1e.com/</platform>)[Partners](https://www.gen1e.com/</partners>)[About](https://www.gen1e.com/</about>)[Media](https://www.gen1e.com/</news>)\\n[Contact Us](https://www.gen1e.com/</contact>)\\n[Contact us](https://www.gen1e.com/</contact>)\\n![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/65771d5bbe02e3b5de648036_profile_Franc%CC%A7ois%20Nader.png)\\n## GEn1E welcomes Fran√ßois Nader, MD, as our Chairman of the Board\\n[Read more](https://www.gen1e.com/<https:/www.globenewswire.com/news-release/2024/12/11/2995272/0/en/GEn1E-Lifesciences-appoints-Fran√ßois-Nader-MD-as-Chair-of-its-Board-of-Directors.html>)\\nWe are a clinical-stage, Phase 2 Company\\n# Accelerating 1st-in-class **precision therapies** for inflammatory & rare diseases\\n**We accelerated from Early Discovery to Phase 2 in**\\n2.5years with seed capital\\nPIPELINE\\n#### Our lead programs\\nWe have 3 key programs in different phases across two different targets. All of these use novel 1st-in-class therapies developed by GEn1E using the relevant modality to treat the disease effectively.\\n[View Pipeline](https://www.gen1e.com/</pipeline>)\\nIV\\np38Œ±:MK2 Dual Signal Modulators\\nARDS\\nGEn-1124\\n[Learn more](https://www.gen1e.com/</ards>)\\nChronic Oral\\np38Œ±:MK2 Dual Signal Modulators\\nStealth\\n[üîí Learn more](https://www.gen1e.com/</contact>)\\nChronic Oral\\nNextGen ERK 1/2 Modulators\\nStealth\\n[üîí Learn more](https://www.gen1e.com/</contact>)\\nPROBLEM\\n### Kinase dysregulation contributes to various inflammatory diseases\\np38, MK2, ERK **kinase dysregulation** contributes to pathogenesis of several devastating inflammatory diseases and therefore are attractive targets. Previous attempts to address this dysregulation involved kinase inhibitors which were **immunosuppressive** and encountered issues including **off-target effects** , **toxicity** , **lack of specificity** , and the potential for severe medical complications. The reason for these issues is because **targeting these kinases with specificity** and without disrupting normal cellular functions is a complex task.\\n![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/657cfd8b1eee1bef26824fd3_binding_pocket%20\\\\(1\\\\).gif)\\nOur Solution\\n### 1. Discovery of a new Binding Pocket\\nTraditional kinase inhibitors focus on the ATP binding pocket with covalent bonding. Our platform allows us to identify new binding pockets where we can target specific functions using allosteric binding.\\n![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/659c5d01c839209823a04b37_MOA.gif)\\n### 2. A unique & validated MOA (presented at ATS 2023 and ATS 2024)\\nGEn1E‚Äôs novel compounds bind to a unique binding site. Unlike previous generation compounds which are non-selective and immunosuppressive due to their inhibitor characteristics, GEn1E‚Äôs selective & dual signal modifiers use a differentiated Mechanism of Action for treating inflammation.\\n[Learn more about our Differentiation](https://www.gen1e.com/</differentiation>)\\n## GRID ‚Ñ¢ AI platform by GEn1E, for GEn1E\\nGEn1E has developed a unique technology platform for treating rare and inflammatory diseases, with a particular focus on Next Generation substrate-specific p38Œ± kinase inhibitors. The key aspects of this platform include a rich database of curated public and proprietary data, which connects the dots between genes, pathways, proteins, diseases, and our compounds. Additionally, the Machine Learning models trained using this data span the entire process chain from drug discovery to clinical trials accelerating the drug development cycle for GEn1E drugs.\\n[Learn more](https://www.gen1e.com/</platform>)\\nOutputs\\n21\\n1st-in-class compounds\\n1\\nAsset in Phase 2\\n3\\nPreclinical programs\\n2.5\\nYears\\nSeed\\nSpend\\nUnique scalability\\n#### Unlocking a $100 Billion+ opportunity\\nWith our mantra of Team + Tech + Target we have enabled a unique and scalable drug development model. We use this model for developing novel 1st-in-class therapies with unprecedented efficiencies. Combining this approach with strategic partnerships enables us to turbocharge and address large unmet needs of devastated patients.\\n![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/65771d5bbe02e3b5de648013_image_Respiratory.png)\\nRespiratory\\nARDS\\n$20B\\nAsthma\\n$40B\\n![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/65771d5bbe02e3b5de648014_image_Neuro_Degenerative.png)\\nNeuro Degenerative\\nVascular Dementia\\n$5B\\n![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/65771d5bbe02e3b5de648012_image_Nephrology.png)\\nNephrology\\nLupus Nephritis\\n$5B\\nAKI\\n$2B\\nTransplant Rejection\\n$1B\\n![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/65771d5bbe02e3b5de648010_image_Musculo%20Skeletal.png)\\nMusculo Skeletal\\nArthritis\\n$60B\\n![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/65771d5bbe02e3b5de648011_image_Dermatology.png)\\nDermatology\\nThermal Injury\\n$2B\\nAtopic Dermatitis\\n$6B\\nNews, PublicatIons & Events\\n#### The latest from GEn1E\\nStay updated on groundbreaking achievements, explore noteworthy publications, and mark your calendar for upcoming events that shape our collective story.\\n[Learn more](https://www.gen1e.com/</news>)\\n[![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e2b/6759e112d6795db2f62dc742_Yahoo%20news.png)NewsGEn1E Lifesciences appoints Fran√ßois Nader, MD as Chair of its Board of Directors](https://www.gen1e.com/<https:/finance.yahoo.com/news/gen1e-lifesciences-appoints-fran-ois-120100489.html?guccounter=1>)\\n[![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e2b/6759e17aa51a82451b6b055b_biospace.png)NewsGEn1E Publishes Breakthrough Research Unveiling Novel MOA of Dual Signal Modulators for Anti-inflammatory and Endothelial-Stabilizing Therapies](https://www.gen1e.com/<https:/www.biospace.com/press-releases/gen1e-lifesciences-publishes-breakthrough-research-unveiling-novel-mechanism-of-action-of-dual-signal-modulators-for-anti-inflammatory-and-endothelial-stabilizing-therapies>)\\nMain pages\\n[Home](https://www.gen1e.com/</>)[Pipeline](https://www.gen1e.com/</pipeline>)[Differentiation](https://www.gen1e.com/</differentiation>)[AI Platform](https://www.gen1e.com/</platform>)[Partners](https://www.gen1e.com/</partners>)[About](https://www.gen1e.com/</about>)[Media](https://www.gen1e.com/</news>)[Contact us](https://www.gen1e.com/</contact>)[Policies](https://www.gen1e.com/</policies>)\\n[![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/65772b2096b2da706407cea3_GEn1E%20Coloured.png)](https://www.gen1e.com/</>)\\n¬© Copyright 2018-2024. All rights reserved.\\n[![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/657c53b3074c37de12878216_Platform%3DX%20\\\\(Twitter\\\\)%2C%20Color%3DOriginal.svg)](https://www.gen1e.com/<https:/twitter.com/gen1elifesci>)[![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/657c53b3fc286d794621bb3b_Platform%3DLinkedIn%2C%20Color%3DOriginal.svg)](https://www.gen1e.com/<https:/www.linkedin.com/company/gen1e-lifesciences>)\\nThis website stores cookies on your computer and we use the cookies to optimize your user experience and allow us to improve our website. By continuing to use our site, clicking \"Accept Cookies\", or closing this banner, you agree to the terms of our [Website Privacy Policy.](https://www.gen1e.com/<#>)CALIFORNIA RESIDENTS: If you would like to exercise any of your consumer privacy rights under the California Consumer Privacy Act (‚ÄúCCPA‚Äù), please click here to access the [CCPA Privacy Policy.](https://www.gen1e.com/<#>)\\n[Accept Cookies](https://www.gen1e.com/<#>)\\n' markdown_with_citations='![‚ü®1‚ü©.svg)](https://www.gen1e.com/</>)\\nPipeline‚ü®2‚ü©Differentiation‚ü®3‚ü©AI Platform‚ü®4‚ü©Partners‚ü®5‚ü©About‚ü®6‚ü©Media‚ü®7‚ü©\\nContact Us‚ü®8‚ü©\\nContact us‚ü®8‚ü©\\n![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/65771d5bbe02e3b5de648036_profile_Franc%CC%A7ois%20Nader.png)\\n## GEn1E welcomes Fran√ßois Nader, MD, as our Chairman of the Board\\nRead more‚ü®9‚ü©\\nWe are a clinical-stage, Phase 2 Company\\n# Accelerating 1st-in-class **precision therapies** for inflammatory & rare diseases\\n**We accelerated from Early Discovery to Phase 2 in**\\n2.5years with seed capital\\nPIPELINE\\n#### Our lead programs\\nWe have 3 key programs in different phases across two different targets. All of these use novel 1st-in-class therapies developed by GEn1E using the relevant modality to treat the disease effectively.\\nView Pipeline‚ü®2‚ü©\\nIV\\np38Œ±:MK2 Dual Signal Modulators\\nARDS\\nGEn-1124\\nLearn more‚ü®10‚ü©\\nChronic Oral\\np38Œ±:MK2 Dual Signal Modulators\\nStealth\\nüîí Learn more‚ü®8‚ü©\\nChronic Oral\\nNextGen ERK 1/2 Modulators\\nStealth\\nüîí Learn more‚ü®8‚ü©\\nPROBLEM\\n### Kinase dysregulation contributes to various inflammatory diseases\\np38, MK2, ERK **kinase dysregulation** contributes to pathogenesis of several devastating inflammatory diseases and therefore are attractive targets. Previous attempts to address this dysregulation involved kinase inhibitors which were **immunosuppressive** and encountered issues including **off-target effects** , **toxicity** , **lack of specificity** , and the potential for severe medical complications. The reason for these issues is because **targeting these kinases with specificity** and without disrupting normal cellular functions is a complex task.\\n![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/657cfd8b1eee1bef26824fd3_binding_pocket%20\\\\(1\\\\).gif)\\nOur Solution\\n### 1. Discovery of a new Binding Pocket\\nTraditional kinase inhibitors focus on the ATP binding pocket with covalent bonding. Our platform allows us to identify new binding pockets where we can target specific functions using allosteric binding.\\n![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/659c5d01c839209823a04b37_MOA.gif)\\n### 2. A unique & validated MOA (presented at ATS 2023 and ATS 2024)\\nGEn1E‚Äôs novel compounds bind to a unique binding site. Unlike previous generation compounds which are non-selective and immunosuppressive due to their inhibitor characteristics, GEn1E‚Äôs selective & dual signal modifiers use a differentiated Mechanism of Action for treating inflammation.\\nLearn more about our Differentiation‚ü®3‚ü©\\n## GRID ‚Ñ¢ AI platform by GEn1E, for GEn1E\\nGEn1E has developed a unique technology platform for treating rare and inflammatory diseases, with a particular focus on Next Generation substrate-specific p38Œ± kinase inhibitors. The key aspects of this platform include a rich database of curated public and proprietary data, which connects the dots between genes, pathways, proteins, diseases, and our compounds. Additionally, the Machine Learning models trained using this data span the entire process chain from drug discovery to clinical trials accelerating the drug development cycle for GEn1E drugs.\\nLearn more‚ü®4‚ü©\\nOutputs\\n21\\n1st-in-class compounds\\n1\\nAsset in Phase 2\\n3\\nPreclinical programs\\n2.5\\nYears\\nSeed\\nSpend\\nUnique scalability\\n#### Unlocking a $100 Billion+ opportunity\\nWith our mantra of Team + Tech + Target we have enabled a unique and scalable drug development model. We use this model for developing novel 1st-in-class therapies with unprecedented efficiencies. Combining this approach with strategic partnerships enables us to turbocharge and address large unmet needs of devastated patients.\\n![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/65771d5bbe02e3b5de648013_image_Respiratory.png)\\nRespiratory\\nARDS\\n$20B\\nAsthma\\n$40B\\n![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/65771d5bbe02e3b5de648014_image_Neuro_Degenerative.png)\\nNeuro Degenerative\\nVascular Dementia\\n$5B\\n![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/65771d5bbe02e3b5de648012_image_Nephrology.png)\\nNephrology\\nLupus Nephritis\\n$5B\\nAKI\\n$2B\\nTransplant Rejection\\n$1B\\n![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/65771d5bbe02e3b5de648010_image_Musculo%20Skeletal.png)\\nMusculo Skeletal\\nArthritis\\n$60B\\n![](https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/65771d5bbe02e3b5de648011_image_Dermatology.png)\\nDermatology\\nThermal Injury\\n$2B\\nAtopic Dermatitis\\n$6B\\nNews, PublicatIons & Events\\n#### The latest from GEn1E\\nStay updated on groundbreaking achievements, explore noteworthy publications, and mark your calendar for upcoming events that shape our collective story.\\nLearn more‚ü®7‚ü©\\n![‚ü®11‚ü©NewsGEn1E Lifesciences appoints Fran√ßois Nader, MD as Chair of its Board of Directors](https://www.gen1e.com/<https:/finance.yahoo.com/news/gen1e-lifesciences-appoints-fran-ois-120100489.html?guccounter=1>)\\n![‚ü®12‚ü©NewsGEn1E Publishes Breakthrough Research Unveiling Novel MOA of Dual Signal Modulators for Anti-inflammatory and Endothelial-Stabilizing Therapies](https://www.gen1e.com/<https:/www.biospace.com/press-releases/gen1e-lifesciences-publishes-breakthrough-research-unveiling-novel-mechanism-of-action-of-dual-signal-modulators-for-anti-inflammatory-and-endothelial-stabilizing-therapies>)\\nMain pages\\nHome‚ü®13‚ü©Pipeline‚ü®2‚ü©Differentiation‚ü®3‚ü©AI Platform‚ü®4‚ü©Partners‚ü®5‚ü©About‚ü®6‚ü©Media‚ü®7‚ü©Contact us‚ü®8‚ü©Policies‚ü®14‚ü©\\n![‚ü®15‚ü©](https://www.gen1e.com/</>)\\n¬© Copyright 2018-2024. All rights reserved.\\n![‚ü®16‚ü©%2C%20Color%3DOriginal.svg)](https://www.gen1e.com/<https:/twitter.com/gen1elifesci>)![‚ü®17‚ü©](https://www.gen1e.com/<https:/www.linkedin.com/company/gen1e-lifesciences>)\\nThis website stores cookies on your computer and we use the cookies to optimize your user experience and allow us to improve our website. By continuing to use our site, clicking \"Accept Cookies\", or closing this banner, you agree to the terms of our Website Privacy Policy.‚ü®18‚ü©CALIFORNIA RESIDENTS: If you would like to exercise any of your consumer privacy rights under the California Consumer Privacy Act (‚ÄúCCPA‚Äù), please click here to access the CCPA Privacy Policy.‚ü®18‚ü©\\nAccept Cookies‚ü®18‚ü©\\n' references_markdown='\\n\\n## References\\n\\n‚ü®1‚ü© https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/66395347210378818f4c651d_GEn1E%20logo%20horizontal%20\\\\(2\\\\: ![\\n‚ü®2‚ü© https://www.gen1e.com/</pipeline>: Pipeline\\n‚ü®3‚ü© https://www.gen1e.com/</differentiation>: Differentiation\\n‚ü®4‚ü© https://www.gen1e.com/</platform>: AI Platform\\n‚ü®5‚ü© https://www.gen1e.com/</partners>: Partners\\n‚ü®6‚ü© https://www.gen1e.com/</about>: About\\n‚ü®7‚ü© https://www.gen1e.com/</news>: Media\\n‚ü®8‚ü© https://www.gen1e.com/</contact>: Contact Us\\n‚ü®9‚ü© https://www.gen1e.com/<https:/www.globenewswire.com/news-release/2024/12/11/2995272/0/en/GEn1E-Lifesciences-appoints-Fran√ßois-Nader-MD-as-Chair-of-its-Board-of-Directors.html>: Read more\\n‚ü®10‚ü© https://www.gen1e.com/</ards>: Learn more\\n‚ü®11‚ü© https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e2b/6759e112d6795db2f62dc742_Yahoo%20news.png: ![\\n‚ü®12‚ü© https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e2b/6759e17aa51a82451b6b055b_biospace.png: ![\\n‚ü®13‚ü© https://www.gen1e.com/</>: Home\\n‚ü®14‚ü© https://www.gen1e.com/</policies>: Policies\\n‚ü®15‚ü© https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/65772b2096b2da706407cea3_GEn1E%20Coloured.png: ![\\n‚ü®16‚ü© https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/657c53b3074c37de12878216_Platform%3DX%20\\\\(Twitter\\\\: ![\\n‚ü®17‚ü© https://cdn.prod.website-files.com/65771d5bbe02e3b5de647e13/657c53b3fc286d794621bb3b_Platform%3DLinkedIn%2C%20Color%3DOriginal.svg: ![\\n‚ü®18‚ü© https://www.gen1e.com/<#>: Website Privacy Policy.\\n' fit_markdown='' fit_html=''",
  "generated_description": "GEn1E Lifesciences is an ambitious biotech startup that launched in 2018, born from the roundtable discussions of Y Combinator's S19 batch and fueled by a mission that's both noble and urgent: to accelerate the development of therapies for rare and inflammatory diseases through an innovative AI platform. Based in Palo Alto, California, GEn1E has quickly positioned itself as a clinical-stage, multi-target company that‚Äôs making waves in the drug discovery arena.\n\n### The Mission \nAt its core, GEn1E is dedicated to finding effective treatments for diseases that, as it stands, have none‚Äîan alarming statistic that applies to around 90% of rare diseases. Their focus on immunomodulatory therapies aims to change that narrative. By applying advanced AI technologies, GEn1E is not just speeding up the drug development process; it‚Äôs doing so with a brisk efficiency that shatters the norms of the industry, often characterized by $100 million budgets and 7-year timelines.\n\n### The Technology \nGEn1E's proprietary AI platform, GRID‚Ñ¢, stands out by harnessing a wealth of curated data that seamlessly interlinks genes, proteins, and disease pathways to identify promising therapeutic targets. This allows them to pinpoint new binding sites for drug development‚Äîan approach that has led them to identify 21+ first-in-class compounds and move at a dizzying pace from early discovery to Phase 2 clinical trials in just two and a half years. They‚Äôve developed targeted therapies such as their ARDS-specific treatment, sharply aimed at reducing a staggering $20 billion societal cost in the U.S. alone.\n\n### The Pipeline \nCurrently, GEn1E boasts a pipeline with an impressive array of novel therapeutics. They have key programs targeting multiple inflammatory disease pathways using their cutting-edge p38Œ±:MK2 Dual Signal Modulators, among other innovative compounds. In the next year, they plan to fast-track two additional disease targets toward Investigational New Drug (IND) application status.\n\n### The Team \nLed by a seasoned team with extensive experience in drug development and machine learning, GEn1E combines expertise to bridge the gap between technology and therapeutic innovation. Their board recently welcomed Fran√ßois Nader, MD, further bolstering their strategic direction.\n\n### Conclusion\nGEn1E Lifesciences is not just another company in the healthcare space. It embodies a forward-thinking approach that leverages AI to tackle some of medicine's toughest challenges. By focusing on precision therapies for inflammatory and rare diseases, GEn1E is positioned not only to innovate but to transform the lives of patients facing profound health struggles. Keep an eye on this company as it navigates the complexities of drug development and delivers on its promise to improve global healthcare‚Äîone therapy at a time. \n\nFor more information, you can visit [GEn1E Lifesciences](https://www.gen1e.com)."
}